Clinical Efficacy OxyBand offers a FDA-approved wound dressing that delivers pure oxygen for up to five days, with multiple trials showing faster healing, reduced pain and inflammation, and no infections versus standard care. This strong clinical foundation can be positioned to medical centers and wound care clinics as a distinctive differentiator.

Strategic Partnerships Evidence from a major academic medical institution and a published Army Institute for Surgical Research trial underscores validation across diverse wound types and settings. Target hospitals, burn centers, military medical facilities, and veteran care networks as potential early adopters and advocates.

Targeted Markets Besides acute wounds, the technology spans diabetic and chronic ulcers, eye diseases, orthopedics, regenerative medicine, antimicrobial healing, and cosmetic procedures. Develop a tiered outreach plan focusing on large wound care networks, diabetic clinics, and perioperative suites where faster healing reduces costs and bed days.

Growth Readiness With a small team and currently under $1M revenue, there is room to leverage partnerships with larger medical device distributors, contract manufacturers, and regulatory consultants to scale manufacturing, distribution, and clinical studies, accelerating go-to-market efforts.

Competitive Positioning Distinct advantage as a first-to-market, oxygen-delivery wound dressing with FDA clearance and proven outcome reductions. Emphasize cost-of-care savings, infection risk mitigation, and faster return-to-work metrics in sales discussions to differentiate from traditional dressings and other wound care therapies.